Chinese Medical Journal - Pulmonary and Critical Care Medicine,
Год журнала:
2024,
Номер
2(1), С. 42 - 47
Опубликована: Фев. 6, 2024
Lung
cancer
is
a
leading
cause
of
deaths
worldwide,
consisting
two
major
histological
subtypes:
small-cell
lung
(SCLC)
and
non-small-cell
(NSCLC).
In
some
cases,
NSCLC
patients
may
undergo
transformation
to
SCLC
during
clinical
treatments,
which
associated
with
resistance
targeted
therapy,
immunotherapy,
or
chemotherapy.
The
review
provides
comprehensive
analysis
from
NSCLC,
including
biological
mechanism,
relevance,
potential
treatment
options
after
transformation,
give
better
understanding
provide
support
for
further
research
define
therapy
options.
Radiation Oncology,
Год журнала:
2023,
Номер
18(1)
Опубликована: Ноя. 16, 2023
Abstract
Purpose
To
discuss
the
optimal
treatment
modality
for
inoperable
locally
advanced
Non-Small
Cell
Lung
Cancer
patients
with
poor
physical
status,
impaired
cardio-pulmonary
function,
and
negative
driver
genes,
provide
clinical
evidence.
Materials
methods
Retrospective
analysis
of
62
cases
non-small
cell
lung
cancer
genes
treated
at
Tsukuba
University
Hospital(Japan)
Qingdao
Affiliated
Hospital(China).The
former
received
proton
therapy
concurrent
chemotherapy,
referred
to
as
group,
25
included;
while
latter
underwent
X-ray
chemoradiotherapy
followed
by
1
year
sequential
immunomodulatory
maintenance
therapy,
37
included.The
response
adverse
reactions
were
assessed
using
RECIST
v1.1
criteria
CTCAE
v3.0,
radiotherapy
planning
evaluation
organs
risk
performed
CB-CHOP
method.All
data
subjected
statistical
GraphPad
Prism
v9.0,
a
T-test
P
<
0.05
considered
statistically
significant.
Results
(1)Target
dose
distribution:
compared
group
exhibited
smaller
CTV
field
sizes,
more
pronounced
bragg
peak.(2)Organs
dose:
When
comparing
doses
(V5,
V20,
MLD)
heart
(V40,
Dmax)
lower,
significance
(
0.05),
spinal
cord
esophagus
showed
no
significant
differences
between
two
groups
>
0.05).(3)Treatment-related
toxicities:
The
incidence
grade
3
or
higher
events
in
was
28.6%
4.2%,
respectively,
difference
0.05).
In
terms
types
events,
primarily
experienced
esophagitis
pneumonia,
esophagitis,
myocarditis.
Both
did
not
experience
radiation
myelitis
esophagotracheal
fistula.(4)Efficacy
evaluation:
RR
68.1%
70.2%,
respectively
DCR
92.2%
86.4%,
indicating
short-term
efficacy
modalities.(5)Survival
status:
PFS
31.6
±
3.5
months
(95%
CI:
24.7
~
38.5)
24.9
1.55
21.9
27.9),
OS
51.6
4.62
42.5
60.7)
33.1
1.99
29.2
37.1),
0.05).According
annual-specific
analysis,
rates
first
third
years
both
follows:
100%,
56.1%
32.5%
vs.
54.3%
26.3%
group.
No
observed
each
time
point
0.05).The
88.2%,
76.4%
91.4%,
46.3%
There
second
but
Survival
curve
graphs
also
depicted
similar
trend.
Conclusion
within
years.
However,
demonstrated
clear
advantage
over
year.
This
suggests
suitable
evidence
populations
frail
health,
compromised
post-COVID-19
sequelae,
underlying
comorbidities.
JCO Precision Oncology,
Год журнала:
2023,
Номер
7
Опубликована: Янв. 1, 2023
Many
patients
with
actionable
driver
oncogenes
(ADOs)
are
never
identified
and
thus
receive
targeted
treatment.
This
study
evaluated
the
economic
impact
potential
life-years
gained
(LYG)
that
can
be
attributed
to
extent
of
next-generation
sequencing
(NGS)
testing
in
United
States
compared
single-gene
(SGT)
metastatic
nonsquamous
non-small-cell
lung
cancer
States.A
model
was
developed
evaluate
incremental
rates
SGT
or
NSG
on
basis
LYG
cost
per
LYG.
ADOs
included
for
NGS
EGFR,
ALK,
ROS1,
BRAF,
RET,
MET,
NTRK.
EGFR
ALK.
Assumptions
were
made
expected
incidence
ADOs.
Survival
distributions
fit
published
trial
averages
median
5-year
overall
survival.
Treatment
costs
estimated
from
drug
averages.
Reimbursement
based
data
Center
Medicare
Medicaid
Services.Each
10%
increase
produces
an
average
2,627.4
additional
LYG,
savings
$75
US
dollars
(USD).
Replacing
at
current
rate
80%
would
result
21,09.6
reduce
by
$599
USD.
If
100%
eligible
tested
each
patient
had
matched
treatment,
total
$16,641.57
USD.On
evidence,
population-level
simulations
demonstrate
clinically
relevant
gains
survival
non-negligible
reduction
obtainable
widespread
adoption
appropriate
treatment
matching
advanced
cancer.
Abstract
Background
Metabolic
disturbance
is
a
hallmark
of
cancers.
Targeting
key
metabolic
pathways
and
metabolism‐related
molecular
could
be
potential
therapeutic
approach.
Uncoupling
protein
2
(UCP2)
plays
pivotal
part
in
the
malignancy
cancer
its
capacity
to
develop
resistance
pharmaceutical
interventions.
However,
it
unclear
about
mechanism
how
UCP2
acts
tumor
growth
reprogramming
process
non‐small
cell
lung
(NSCLC).
Methods
Here,
we
conducted
qRT‐PCR
investigate
expression
both
NSCLC
tissues
lines.
Subsequent
functional
studies
including
colony
formation
assay,
CCK‐8
glycolysis
assay
were
functions
NSCLC.
The
regulatory
toward
mammalian
target
rapamycin
(mTOR)
hypoxia‐inducible
factor‐1
alpha
(HIF‐1α)
signaling
was
confirmed
through
western
blotting.
Results
We
observed
significant
upregulation
increased
has
strong
association
with
worse
outlook.
Silencing
remarkably
dampened
proliferation
capacities.
Mechanically,
promoted
tumorigenesis
partially
via
regulating
mTOR/HIF‐1α
axis.
Conclusion
Taken
together,
explored
as
well
mechanisms
UCP2/mTOR/HIF‐1α
axis
progression,
uncovering
biological
signatures
targets
for
treatment.
Chinese Medical Journal - Pulmonary and Critical Care Medicine,
Год журнала:
2024,
Номер
2(1), С. 42 - 47
Опубликована: Фев. 6, 2024
Lung
cancer
is
a
leading
cause
of
deaths
worldwide,
consisting
two
major
histological
subtypes:
small-cell
lung
(SCLC)
and
non-small-cell
(NSCLC).
In
some
cases,
NSCLC
patients
may
undergo
transformation
to
SCLC
during
clinical
treatments,
which
associated
with
resistance
targeted
therapy,
immunotherapy,
or
chemotherapy.
The
review
provides
comprehensive
analysis
from
NSCLC,
including
biological
mechanism,
relevance,
potential
treatment
options
after
transformation,
give
better
understanding
provide
support
for
further
research
define
therapy
options.
